Literature DB >> 12905475

Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients.

Gunhild Lien1, Berit Flatø, Margaretha Haugen, Odd Vinje, Dag Sørskaar, Knut Dale, Virginia Johnston, Thore Egeland, Øystein Førre.   

Abstract

OBJECTIVE: To determine the frequency of low bone mineral content (BMC) and low bone mineral density (BMD) as long-term complications in adolescents with early-onset juvenile idiopathic arthritis (JIA), and to identify disease variables, patient characteristics, and biochemical bone markers related to low bone mass.
METHODS: One hundred five (87%) of 121 adolescent patients with early-onset JIA (ages 13-19 years, 80 girls and 25 boys, mean age at onset of JIA 2.8 years), from a cohort first admitted to the hospital between 1980 and 1985, were assessed after a mean disease duration of 14.2 years. BMC and BMD of the total body, the lumbar spine at L2-L4, and the femoral neck were measured by dual-energy x-ray absorptiometry. Age- and sex-specific reference values from a pooled, healthy reference population were used to calculate Z scores. Low bone mass was defined as a Z score less than -1 SD.
RESULTS: Among the 103 adolescent JIA patients who underwent total-body imaging, 41% had low total-body BMC and 34% had low total-body BMD. Compared with adolescent JIA patients who had normal total-body BMC, those with low BMC had lower mean weight (P < 0.001), height (P < 0.001), lean mass (P < 0.001), and remission rates (P = 0.016), had longer duration of active disease (P = 0.013), had higher numbers of active and mobility-restricted joints (P < 0.001 and P = 0.001, respectively), had more disability (P = 0.011), had higher frequencies of joint erosions (P < 0.001), and had higher erythrocyte sedimentation rates (P = 0.033). In multiple linear regression analyses of total-body BMC, 88% of the variance was explained by the duration of active disease, the number of joints with restricted mobility, the bone area, urinary deoxypyridinoline values, age, weight, and height.
CONCLUSION: Forty-one percent of the adolescents with early-onset JIA had low bone mass >11 years after disease onset. The development of low total-body BMC was related to the duration of active disease, disease severity, measures of bone resorption, weight, and height.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12905475     DOI: 10.1002/art.11097

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

Review 1.  Osteoporosis in juvenile idiopathic arthritis--a practical approach to diagnosis and therapy.

Authors:  Johannes Roth; Susanne Bechtold; Gudrun Borte; Frank Dressler; Hermann J Girschick; Michael Borte
Journal:  Eur J Pediatr       Date:  2007-04-14       Impact factor: 3.183

Review 2.  Management of juvenile idiopathic arthritis: hitting the target.

Authors:  Claas Hinze; Faekah Gohar; Dirk Foell
Journal:  Nat Rev Rheumatol       Date:  2015-01-06       Impact factor: 20.543

3.  [Bone density measurements on growing skeletons and the clinical consequences].

Authors:  S Bechtold-Dalla Pozza
Journal:  Z Rheumatol       Date:  2011-12       Impact factor: 1.372

4.  Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study.

Authors:  Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M Huber; David A Cabral; Rosie Scuccimarri; Paivi M Miettunen; Johannes Roth; Stephanie A Atkinson; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; Maryann Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-01       Impact factor: 4.794

5.  Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders.

Authors:  A M Huber; I Gaboury; D A Cabral; B Lang; A Ni; D Stephure; S Taback; P Dent; J Ellsworth; C LeBlanc; C Saint-Cyr; R Scuccimarri; J Hay; B Lentle; M Matzinger; N Shenouda; D Moher; F Rauch; K Siminoski; L M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-04       Impact factor: 4.794

Review 6.  Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Authors:  Yujuan Zhang; Diana Milojevic
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

7.  Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits.

Authors:  Jon M Burnham; Justine Shults; Sarah E Dubner; Harjeet Sembhi; Babette S Zemel; Mary B Leonard
Journal:  Arthritis Rheum       Date:  2008-08

Review 8.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

9.  Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNFα therapy and discontinuation of glucocorticoids.

Authors:  Kristyna Brabnikova Maresova; Katerina Jarosova; Karel Pavelka; Jan J Stepan
Journal:  Rheumatol Int       Date:  2013-02-01       Impact factor: 2.631

Review 10.  Long-term bone health in glucocorticoid-treated children with rheumatic diseases.

Authors:  Isabelle Rousseau-Nepton; Bianca Lang; Celia Rodd
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.